259 related articles for article (PubMed ID: 34780576)
21. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
[TBL] [Abstract][Full Text] [Related]
22. Antiviral therapeutics for chikungunya virus.
Ghildiyal R; Gabrani R
Expert Opin Ther Pat; 2020 Jun; 30(6):467-480. PubMed ID: 32249636
[No Abstract] [Full Text] [Related]
23. A combination of doxycycline and ribavirin alleviated chikungunya infection.
Rothan HA; Bahrani H; Mohamed Z; Teoh TC; Shankar EM; Rahman NA; Yusof R
PLoS One; 2015; 10(5):e0126360. PubMed ID: 25970853
[TBL] [Abstract][Full Text] [Related]
24. TLR4 is one of the receptors for Chikungunya virus envelope protein E2 and regulates virus induced pro-inflammatory responses in host macrophages.
Mahish C; De S; Chatterjee S; Ghosh S; Keshry SS; Mukherjee T; Khamaru S; Tung KS; Subudhi BB; Chattopadhyay S; Chattopadhyay S
Front Immunol; 2023; 14():1139808. PubMed ID: 37153546
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus.
Rothan HA; Bahrani H; Shankar EM; Rahman NA; Yusof R
Antiviral Res; 2014 Aug; 108():173-80. PubMed ID: 24929084
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of transient receptor potential vanilloid 1 (TRPV1) channel regulates chikungunya virus infection in macrophages.
Sanjai Kumar P; Nayak TK; Mahish C; Sahoo SS; Radhakrishnan A; De S; Datey A; Sahu RP; Goswami C; Chattopadhyay S; Chattopadhyay S
Arch Virol; 2021 Jan; 166(1):139-155. PubMed ID: 33125586
[TBL] [Abstract][Full Text] [Related]
27. Vathasura Kudineer, an Andrographis based polyherbal formulation exhibits immunomodulation and inhibits chikungunya virus (CHIKV) under invitro conditions.
Hasan A; Devi Ms S; Sharma G; Narayanan V; Sathiyarajeswaran P; Vinayak S; Sunil S
J Ethnopharmacol; 2023 Feb; 302(Pt A):115762. PubMed ID: 36181982
[TBL] [Abstract][Full Text] [Related]
28. Chikungunya virus infections: time to act, time to treat.
Abdelnabi R; Neyts J; Delang L
Curr Opin Virol; 2017 Jun; 24():25-30. PubMed ID: 28414993
[TBL] [Abstract][Full Text] [Related]
29. Tomatidine, a natural steroidal alkaloid shows antiviral activity towards chikungunya virus in vitro.
Troost B; Mulder LM; Diosa-Toro M; van de Pol D; Rodenhuis-Zybert IA; Smit JM
Sci Rep; 2020 Apr; 10(1):6364. PubMed ID: 32286447
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.
Nie X; Chanley MA; Pengal R; Thomas DB; Agrawal S; Smoyer WE
Am J Physiol Renal Physiol; 2018 Apr; 314(4):F602-F613. PubMed ID: 29187369
[TBL] [Abstract][Full Text] [Related]
31. The Host DHX9 DExH-Box Helicase Is Recruited to Chikungunya Virus Replication Complexes for Optimal Genomic RNA Translation.
Matkovic R; Bernard E; Fontanel S; Eldin P; Chazal N; Hassan Hersi D; Merits A; Péloponèse JM; Briant L
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463980
[TBL] [Abstract][Full Text] [Related]
32. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
Front Immunol; 2019; 10():2563. PubMed ID: 31736977
[TBL] [Abstract][Full Text] [Related]
33. MK2 and MK3--a pair of isoenzymes?
Ronkina N; Kotlyarov A; Gaestel M
Front Biosci; 2008 May; 13():5511-21. PubMed ID: 18508601
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virus.
Wada Y; Orba Y; Sasaki M; Kobayashi S; Carr MJ; Nobori H; Sato A; Hall WW; Sawa H
Virology; 2017 May; 505():102-112. PubMed ID: 28236746
[TBL] [Abstract][Full Text] [Related]
35. In vitro Evaluation of Anti-Chikungunya Virus Activities of Tualang Honey.
Barkhadle NI; Mohamud R; Mat Jusoh TNA; Shueb RH
Trop Biomed; 2021 Mar; 38(1):42-49. PubMed ID: 33797523
[TBL] [Abstract][Full Text] [Related]
36. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells.
Khan M; Santhosh SR; Tiwari M; Lakshmana Rao PV; Parida M
J Med Virol; 2010 May; 82(5):817-24. PubMed ID: 20336760
[TBL] [Abstract][Full Text] [Related]
37. Activity of andrographolide against chikungunya virus infection.
Wintachai P; Kaur P; Lee RC; Ramphan S; Kuadkitkan A; Wikan N; Ubol S; Roytrakul S; Chu JJ; Smith DR
Sci Rep; 2015 Sep; 5():14179. PubMed ID: 26384169
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
[TBL] [Abstract][Full Text] [Related]
39. Imidazonaphthyridine effects on Chikungunya virus replication: Antiviral activity by dependent and independent of interferon type 1 pathways.
Ruiz UEA; Santos IA; Grosche VR; Fernandes RS; de Godoy AS; Torres JDA; Freire MCLC; Mesquita NCMR; Guevara-Vega M; Nicolau-Junior N; Sabino-Silva R; Mineo TWP; Oliva G; Jardim ACG
Virus Res; 2023 Jan; 324():199029. PubMed ID: 36565816
[TBL] [Abstract][Full Text] [Related]
40. Current Strategies for Inhibition of Chikungunya Infection.
Subudhi BB; Chattopadhyay S; Mishra P; Kumar A
Viruses; 2018 May; 10(5):. PubMed ID: 29751486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
